BBK Worldwide has expanded its three decades of expertise in supporting clinical R&D with the introduction of its Patient Recruitment Franchise Program at the annual meeting of the DIA in Washington, D.C., 13–17 June 2010. BBK’s flagship product for its new program is the Study eBinder: a flexible and intuitive communication platform that uses the Apple iPad® to facilitate the myriad processes necessary to effectively recruit and manage patients for global clinical trials.
This new franchise model not only realizes significant cost-savings in the execution of patient recruitment programs, it also supports quick, efficient enrollment for multiple studies within the same therapeutic category, as well as multiple protocols for a single compound. “Franchise programs create exponential savings through the economies of scale derived from applying strategies and tactics across multiple studies and countries,” said Joan F. Bachenheimer, BBK Worldwide founding principal and CEO. “Using the model of the Patient Recruitment Franchise Program, sponsors are able to consolidate planning and recruitment strategies for immediate and long-term cost reductions that far exceed preferred pricing or volume discounts.”